Kaneka Eurogentec vs Nitto Denko Avecia: CDMO Comparison

How does Kaneka Eurogentec compare to Nitto Denko Avecia?

As of Aug 2026, Kaneka Eurogentec: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 4 EMA/MHRA GMP certificates. Signal Score 81.6. Nitto Denko Avecia: 4 FDA inspections (including 3 NAI, 1 VAI and 0 OAI). Signal Score 80.3. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Kaneka Eurogentec and Nitto Denko Avecia on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Seraing, BE
Signal Score
82/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
0 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
4
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
mRNA, Plasmid, Oligonucleotide
Milford, MA
Signal Score
80/100
Quality (FDA + GMP)
100/100
FDA inspections
4
— NAI / VAI / OAI
3 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
Oligonucleotide, mRNA

Key differences

  • Nitto Denko Avecia has more FDA inspections on record (4 vs 1) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Kaneka Eurogentec holds 4 active EMA GMP certificates; Nitto Denko Avecia does not appear in EudraGMDP.

Across the cross-modality scorecard, Kaneka Eurogentec carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: Kaneka Eurogentec vs Nitto Denko Avecia

How does Kaneka Eurogentec compare to Nitto Denko Avecia?

On CDMO Signal's composite Signal Score, Kaneka Eurogentec is 82/100 and Nitto Denko Avecia is 80/100; Kaneka Eurogentec has 1 FDA inspection on record vs 4 for Nitto Denko Avecia; European coverage is 4 active EMA+MHRA certificates for Kaneka Eurogentec vs 0 for Nitto Denko Avecia. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Kaneka Eurogentec or Nitto Denko Avecia?

Both Kaneka Eurogentec and Nitto Denko Avecia maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Kaneka Eurogentec has 1 FDA inspection on record; Nitto Denko Avecia has 4.

How do Kaneka Eurogentec and Nitto Denko Avecia compare on European GMP coverage?

Kaneka Eurogentec holds 4 active EMA GMP certificates and 0 MHRA / UK certificates. Nitto Denko Avecia holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

Kaneka Eurogentec carries a Signal Score of 82/100 and Nitto Denko Avecia carries 80/100 — essentially tied for Kaneka Eurogentec. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Kaneka Eurogentec and Nitto Denko Avecia for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.